je.st
news
Tag: dosing
Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
2016-07-22 13:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the companys investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal trial called ONCEMRK. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Carmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Pinch-Valve Dosing System Improves Bag-Filling Accuracy
2016-02-17 22:06:39| Food Processing
Gravimetric DAX-PVS delivers high dosing accuracy with semi-automatic handling.
Tags: system
accuracy
improves
dosing
Comar is Investing in Manufacturing Capabilities for Medication Dosing Cups
2016-02-01 11:31:12| Industrial Newsroom - All News for Today
Company builds on a proven track record of accuracy for its line of dosage cups Buena, NJ Comar LLC, the market-leading supplier of printed dosage cups, has commissioned its third dosage cup printer. The company can now increase production capacity and speed to allow for a stable supply of its existing 20 mL, 30...
Tags: manufacturing
investing
capabilities
medication
Amgen seeks FDA approval for monthly dosing option for Repatha
2015-09-11 17:48:27| Biotech - Topix.net
Amgen Inc said it had asked the U.S. Food and Drug Administration to approve a monthly single-dosing option for its recently approved cholesterol drug, Repatha. The FDA approved Repatha, one of two approved treatments in a new class of injectable "bad" cholesterol-lowering drugs called PCSK9 inhibitors, on Aug. 27. The drug is approved for patients with hereditary forms of high cholesterol - heterozygous familial hypercholesterolemia and a rarer homozygous form of the condition, in addition to those with cardiovascular disease.
Tags: option
monthly
approval
seeks
New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
2015-09-08 07:25:25| drugdiscoveryonline Home Page
Bristol-Myers Squibb Company recently announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC)
Tags: with
advanced
cell
treatment